IRIDEX Corporation (IRIX)
| Market Cap | 117.82M |
| Revenue (ttm) | 39.29M |
| Net Income (ttm) | -6.69M |
| Shares Out | 15.63M |
| EPS (ttm) | -0.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $7.13 |
| Previous Close | $7.54 |
| Change ($) | -0.41 |
| Change (%) | -5.44% |
| Day's Open | 7.61 |
| Day's Range | 6.95 - 7.62 |
| Day's Volume | 90,161 |
| 52-Week Range | 1.46 - 9.71 |
MOUNTAIN VIEW, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021.
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iridex's (IRIX) fourth-quarter 2020 results benefit from strong product line-up and expanding market position.
Iridex (IRIX) delivered earnings and revenue surprises of 90.91% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Iridex (NASDAQ:IRIX) decreased 0.4% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 90.91% year over year to ($0.01), which beat t...
MOUNTAIN VIEW, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 2, 2021.
Iridex (NASDAQ:IRIX) releases its next round of earnings this Monday, March 22. Here is Benzinga's essential guide to Iridex's Q4 earnings report.
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...
IRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2020
MOUNTAIN VIEW, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and full year end...
Iridex Corp. seems to be at the initial stage of a growth inflection that could drive the stock up 175-625%. IRIX has a commercial product which could revolutionize glaucoma treatment, with an addressab...
MOUNTAIN VIEW, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal dis...
IRIDEX's (IRIX) CEO Dave Bruce on Q3 2020 Results - Earnings Call Transcript
Iridex (IRIX) delivered earnings and revenue surprises of 33.33% and 13.08%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MOUNTAIN VIEW, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 26, 2020.
Iridex (NASDAQ: IRIX) unveils its next round of earnings this Monday, November 09. Get prepared with Benzinga's ultimate preview for Iridex's Q3 earnings.
MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Virtual Healthcare Conference.
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2020 after the close of tra...
IRIDEX's (IRIX) CEO Dave Bruce on Q2 2020 Results - Earnings Call Transcript
Iridex Corporation: Deserves More Patience Given Shift In Commercial Strategy And Aggressive Cost Cutting
MOUNTAIN VIEW, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 27, 2020.
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter of 2020 after the close of ...
IRIDEX Corporation (IRIX) CEO David Bruce on Q1 2020 Results - Earnings Call Transcript
Iridex (IRIX) delivered earnings and revenue surprises of 29.41% and -5.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Names Prior CFO/COO as Interim CFO Names Prior CFO/COO as Interim CFO
IRIDEX Corp (IRIX) CEO David Bruce on Q4 2019 Results - Earnings Call Transcript
Iridex (IRIX) delivered earnings and revenue surprises of 31.25% and 0.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
IRIDEX Corp (IRIX) CEO David Bruce on Q3 2019 Results - Earnings Call Transcript
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Robert Gunst as Chairman of the Board, effective October 23, 2019. Concurr...
MOUNTAIN VIEW, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...
Laser Systems & Components Industry Outlook: Prospects Bright
Iridex (IRIX) delivered earnings and revenue surprises of 18.18% and -4.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRIDEX Corp (IRIX) CEO William Moore on Q1 2019 Results - Earnings Call Transcript
Iridex (IRIX) delivered earnings and revenue surprises of 8.33% and 1.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems tha... [Read more...]
| Industry Medical Devices | IPO Date Feb 15, 1996 |
| Stock Exchange NASDAQ | Ticker Symbol IRIX |
Financial Performance
In 2020, IRIX's revenue was $36.35 million, a decrease of -16.34% compared to the previous year's $43.45 million. Losses were -$6.33 million, -28.19% less than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for IRIX stock is "Buy." The 12-month stock price forecast is 10.50, which is an increase of 47.27% from the latest price.